Search

Your search keyword '"Haddad, P."' showing total 13,313 results
Start Over Author "Haddad, P." Publication Type Academic Journals

Refine your results

more »

more »

more »

more »

more »

more »

more »
13,313 results on '"Haddad, P."'

1. Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America

Author

Horberg, Michael, Thompson, Melanie, Agwu, Allison, Colasanti, Jonathan, Haddad, Marwan, Jain, Mamta, McComsey, Grace, Radix, Asa, Rakhmanina, Natella, Short, William R, Singh, Tulika, and Tookes, Hansel

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Pediatric, Aging, Health Services, Sexually Transmitted Infections, Clinical Research, HIV/AIDS, Women's Health, Infectious Diseases, 7.3 Management and decision making, Infection, Good Health and Well Being, HIV care engagement, HIV comorbidities, HIV monitoring, HIV primary care, preventive health, sexually transmitted infections, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

Advances in antiretroviral therapy (ART) have made it possible for persons with human immunodeficiency virus (HIV) to live a lifespan approaching that of people without HIV, without progressing to AIDS or transmitting HIV to sexual partners or infants. There is, therefore, increasing emphasis on maintaining health throughout the lifespan. To receive optimal medical care and achieve desired outcomes, persons with HIV must be consistently engaged in care and able to access uninterrupted treatment, including ART. Comprehensive evidence-based HIV primary care guidance is, therefore, more important than ever. Creating a patient-centered, stigma-free care environment is essential for care engagement. Barriers to care must be decreased at the societal, health system, clinic, and individual levels. As the population ages and noncommunicable diseases arise, providing comprehensive health care for persons with HIV becomes increasingly complex, including management of multiple comorbidities and the associated challenges of polypharmacy, while also attending to HIV-specific health concerns. Clinicians must address issues specific to preventive health, including cancer screening, providing recommended vaccinations, as well as promoting sexual health, including sexually transmitted infection diagnosis, treatment, and prevention. Clinicians also must address issues for specific populations, including persons of childbearing potential, including during preconception and pregnancy; children; adolescents; and transgender and gender-diverse individuals. This guidance from an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America updates the previous 2020 HIV Primary Care Guidance.

Published
2024

2. Expert opinion on the use of contraception in people with multiple sclerosis.

Author

Hillert, Jan, Bove, Riley, Haddad, Lisa, Hellwig, Kerstin, Houtchens, Maria, Magyari, Melinda, Merki-Feld, Gabriele, Montgomery, Scott, Nappi, Rossella, Stenager, Egon, Thompson, Heidi, Tulek, Zeliha, Verdun Di Cantogno, Elisabetta, and Simoni, Manuela

Subjects
Multiple sclerosis, consensus, contraception, disease-modifying therapy, expert opinion, reproductive health, Humans, Multiple Sclerosis, Contraception, Female, Consensus, Male, Delphi Technique, Expert Testimony
Abstract

BACKGROUND: Current guidance on the selection of appropriate contraception for people with multiple sclerosis (PwMS) is lacking. OBJECTIVE: To address this gap, an expert-led consensus program developed recommendations to support clinicians in discussing family planning and contraception with women and men with multiple sclerosis (MS). METHODS: A multidisciplinary steering committee (SC) of 13 international clinical experts led the program, supported by an extended faculty of 32 experts representing 18 countries. A modified Delphi methodology was used for decision-making and consensus-building. The SC drafted 15 clinical questions focused on patient-centered care, selection of contraception, and timing of stopping/starting contraception and disease-modifying therapies (DMTs). Statements addressing each question were drafted based on evaluation of published evidence and the experts clinical experience. Consensus was reached if ⩾75% of respondents agreed (scoring 7-9 on a 9-point scale) with each recommendation. RESULTS: Consensus was reached on 24 of 25 proposed recommendations, including how and when to discuss contraception, types and safety of contraceptives, and how to evaluate the most appropriate contraceptive options for specific patient groups, including those with significant disability or being treated with DMTs. CONCLUSION: These expert recommendations provide the first practical, relevant, and comprehensive guidance for clinicians on the selection of contraception in PwMS.

Published
2024

3. LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia

Author

Wintering, Astrid, Hecht, Anna, Meyer, Julia, Wong, Eric B, Hübner, Juwita, Abelson, Sydney, Feldman, Kira, Kennedy, Vanessa E, Peretz, Cheryl AC, French, Deborah L, Maguire, Jean Ann, Jobaliya, Chintan, Vasquez, Marta Rojas, Desai, Sunil, Dulman, Robin, Nemecek, Eneida, Haines, Hilary, Hammad, Mahmoud, El Haddad, Alaa, Kogan, Scott C, Abdullaev, Zied, Chehab, Farid F, Tasian, Sarah K, Smith, Catherine C, Loh, Mignon L, and Stieglitz, Elliot

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Childhood Leukemia, Hematology, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Stem Cell Research - Nonembryonic - Non-Human, Genetics, Pediatric, Stem Cell Research, Stem Cell Research - Induced Pluripotent Stem Cell, Rare Diseases, 2.1 Biological and endogenous factors, Humans, Leukemia, Myelomonocytic, Juvenile, Adaptor Proteins, Signal Transducing, Male, Female, Infant, Child, Preschool, Mutation, Intracellular Signaling Peptides and Proteins, Child, Signal Transduction, Pyrazoles, Nitriles, Pyrimidines, Immunology
Abstract

Mutations in five canonical Ras pathway genes (NF1, NRAS, KRAS, PTPN11 and CBL) are detected in nearly 90% of patients with juvenile myelomonocytic leukemia (JMML), a frequently fatal malignant neoplasm of early childhood. In this report, we describe seven patients diagnosed with SH2B3-mutated JMML, including five patients who were found to have initiating, loss-of-function mutations in the gene. SH2B3 encodes the adaptor protein LNK, a negative regulator of normal hematopoiesis upstream of the Ras pathway. These mutations were identified to be germline, somatic or a combination of both. Loss of function of LNK, which has been observed in other myeloid malignancies, results in abnormal proliferation of hematopoietic cells due to cytokine hypersensitivity and activation of the JAK/STAT signaling pathway. In vitro studies of induced pluripotent stem cell-derived JMML-like hematopoietic progenitor cells also demonstrated sensitivity of SH2B3-mutated hematopoietic progenitor cells to JAK inhibition. Lastly, we describe two patients with JMML and SH2B3 mutations who were treated with the JAK1/2 inhibitor ruxolitinib. This report expands the spectrum of initiating mutations in JMML and raises the possibility of targeting the JAK/STAT pathway in patients with SH2B3 mutations.

Published
2024

5. Time of sample collection is critical for the replicability of microbiome analyses

Author

Allaband, Celeste, Lingaraju, Amulya, Flores Ramos, Stephany, Kumar, Tanya, Javaheri, Haniyeh, Tiu, Maria D, Dantas Machado, Ana Carolina, Richter, R Alexander, Elijah, Emmanuel, Haddad, Gabriel G, Leone, Vanessa A, Dorrestein, Pieter C, Knight, Rob, and Zarrinpar, Amir

Subjects
Medical Biochemistry and Metabolomics, Medical Physiology, Biomedical and Clinical Sciences, Nutrition and Dietetics, Microbiome, Genetics, Animals, Mice, Microbiota, Male, Specimen Handling, RNA, Ribosomal, 16S, Time Factors, Reproducibility of Results, Circadian Rhythm, Retrospective Studies, Medical biochemistry and metabolomics, Medical physiology, Nutrition and dietetics
Abstract

As the microbiome field moves from descriptive and associative research to mechanistic and interventional studies, being able to account for all confounding variables in the experimental design, which includes the maternal effect1, cage effect2, facility differences3, as well as laboratory and sample handling protocols4, is critical for interpretability of results. Despite significant procedural and bioinformatic improvements, unexplained variability and lack of replicability still occur. One underexplored factor is that the microbiome is dynamic and exhibits diurnal oscillations that can change microbiome composition5-7. In this retrospective analysis of 16S amplicon sequencing studies in male mice, we show that sample collection time affects the conclusions drawn from microbiome studies and its effect size is larger than those of a daily experimental intervention or dietary changes. The timing of divergence of the microbiome composition between experimental and control groups is unique to each experiment. Sample collection times as short as only 4 hours apart can lead to vastly different conclusions. Lack of consistency in the time of sample collection may explain poor cross-study replicability in microbiome research. The impact of diurnal rhythms on the outcomes and study design of other fields is unknown but likely significant.

Published
2024

8. Is the information provided by large language models valid in educating patients about adolescent idiopathic scoliosis? An evaluation of content, clarity, and empathy: The perspective of the European Spine Study Group

Author

Lang, Siegmund, Vitale, Jacopo, Galbusera, Fabio, Fekete, Tamás, Boissiere, Louis, Charles, Yann Philippe, Yucekul, Altug, Yilgor, Caglar, Núñez-Pereira, Susana, Haddad, Sleiman, Gomez-Rice, Alejandro, Mehta, Jwalant, Pizones, Javier, Pellisé, Ferran, Obeid, Ibrahim, Alanay, Ahmet, Kleinstück, Frank, and Loibl, Markus

Published
2024
Full Text
View/download PDF

10. Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO/ASMBS)

Author

De Luca, Maurizio, Shikora, Scott, Eisenberg, Dan, Angrisani, Luigi, Parmar, Chetan, Alqahtani, Aayed, Aminian, Ali, Aarts, Edo, Brown, Wendy, Cohen, Ricardo V., Di Lorenzo, Nicola, Faria, Silvia L., Goodpaster, Kasey P. S., Haddad, Ashraf, Herrera, Miguel, Rosenthal, Raul, Himpens, Jacques, Iossa, Angelo, Kermansaravi, Mohammad, Kow, Lilian, Kurian, Marina, Chiappetta, Sonja, LaMasters, Teresa, Mahawar, Kamal, Merola, Giovanni, Nimeri, Abdelrahman, O’Kane, Mary, Papasavas, Pavlos, Piatto, Giacomo, Ponce, Jaime, Prager, Gerhard, Pratt, Janey S. A., Rogers, Ann M., Salminen, Paulina, Steele, Kimberley E., Suter, Michel, Tolone, Salvatore, Vitiello, Antonio, Zappa, Marco, and Kothari, Shanu N.

Published
2024
Full Text
View/download PDF

23. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community

Author

Cuglievan, Branko, Kantarjian, Hagop, Rubnitz, Jeffrey E., Cooper, Todd M., Zwaan, C. Michel, Pollard, Jessica A., DiNardo, Courtney D., Kadia, Tapan M., Guest, Erin, Short, Nicholas J., McCall, David, Daver, Naval, Nunez, Cesar, Haddad, Fadi G., Garcia, Miriam, Bhalla, Kapil N., Maiti, Abhishek, Catueno, Samanta, Fiskus, Warren, Carter, Bing Z., Gibson, Amber, Roth, Michael, Khazal, Sajad, Tewari, Priti, Abbas, Hussein A., Bourgeois, Wallace, Andreeff, Michael, Shukla, Neerav N., Truong, Danh D., Connors, Jeremy, Ludwig, Joseph A., Stutterheim, Janine, Salzer, Elisabeth, Juul-Dam, Kristian L., Sasaki, Koji, Mahadeo, Kris M., Tasian, Sarah K., Borthakur, Gautam, Dickson, Samantha, Jain, Nitin, Jabbour, Elias, Meshinchi, Soheil, Garcia-Manero, Guillermo, Ravandi, Farhad, Stein, Eytan M., Kolb, E. Anders, and Issa, Ghayas C.

Published
2024
Full Text
View/download PDF

38. Metabolic and Bariatric Surgeon Criteria—An International Experts’ Consensus

Author

Kermansaravi, Mohammad, Chiappetta, Sonja, Shikora, Scott A., Musella, Mario, Kow, Lilian, Aarts, Edo, Abbas, Syed Imran, Aly, Ahmad, Aminian, Ali, Angrisani, Luigi, Asghar, Syed Tanseer, Bashir, Ahmad, Behrens, Estuardo, Billy, Helmuth, Boza, Camilo, Brown, Wendy A., Caina, Daniel Oscar, Carbajo, Miguel A., Chevallier, Jean-Marc, Clapp, Benjamin, Cohen, Ricardo V., Jazi, Amir Hossein Davarpanah, De Luca, Maurizio, Dilemans, Bruno, Fried, Martin, Gagner, Michel, Neto, Manoel Galvao, Garneau, Pierre Y., Gawdat, Khaled, Ghanem, Omar M., Al Hadad, Mohammed, Haddad, Ashraf, ElFawal, Mohamad Hayssam, Herrera, Miguel F., Higa, Kelvin, Himpens, Jaques, Husain, Farah, Kasama, Kazunori, Kassir, Radwan, Khoursheed, Mousa, Khwaja, Haris, Kristinsson, Jon A., Kroh, Matthew, Kurian, Marina S., Lakdawala, Muffazal, LaMasters, Teresa, Lee, Wei-Jei, Madhok, Brijesh, Mahawar, Kamal, Mahdy, Tarek, Almomani, Hazem, Melissas, John, Miller, Karl, Neimark, Alexander, Omarov, Taryel, Palermo, Mariano, Papasavas, Pavlos K., Parmar, Chetan, Pazouki, Abdolreza, Peterli, Ralph, Pintar, Tadeja, Poggi, Luis, Ponce, Jaime, Prasad, Arun, Pratt, Janey S. A., Ramos, Almino C., Rezvani, Masoud, Rheinwalt, Karl, Ribeiro, Rui, Ruiz-Ucar, Elena, Sabry, Karim, Safadi, Bassem, Shabbir, Asim, ShahabiShahmiri, Shahab, Stenberg, Erik, Suter, Michel, Taha, Safwan, Taskin, Halit Eren, Torres, Antonio, Verboonen, Sergio, Vilallonga, Ramon, Voon, Kelvin, Wafa, Ala, Wang, Cunchuan, Weiner, Rudolf, Yang, Wah, Zundel, Natan, Prager, Gerhard, and Nimeri, Abdelrahman

Published
2024
Full Text
View/download PDF

49. Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality

Author

Gygi, Jeremy P, Maguire, Cole, Patel, Ravi K, Shinde, Pramod, Konstorum, Anna, Shannon, Casey P, Xu, Leqi, Hoch, Annmarie, Jayavelu, Naresh Doni, Haddad, Elias K, Network, IMPACC, Reed, Elaine F, Kraft, Monica, McComsey, Grace A, Metcalf, Jordan P, Ozonoff, Al, Esserman, Denise, Cairns, Charles B, Rouphael, Nadine, Bosinger, Steven E, Kim-Schulze, Seunghee, Krammer, Florian, Rosen, Lindsey B, van Bakel, Harm, Wilson, Michael, Eckalbar, Walter L, Maecker, Holden T, Langelier, Charles R, Steen, Hanno, Altman, Matthew C, Montgomery, Ruth R, Levy, Ofer, Melamed, Esther, Pulendran, Bali, Diray-Arce, Joann, Smolen, Kinga K, Fragiadakis, Gabriela K, Becker, Patrice M, Sekaly, Rafick P, Ehrlich, Lauren IR, Fourati, Slim, Peters, Bjoern, Kleinstein, Steven H, and Guan, Leying

Subjects
Biomedical and Clinical Sciences, Immunology, Clinical Research, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Humans, COVID-19, Male, Longitudinal Studies, SARS-CoV-2, Female, Middle Aged, Severity of Illness Index, Aged, Adult, Cytokines, Multiomics, IMPACC Network, Adaptive immunity, Innate immunity, Medical and Health Sciences, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BACKGROUNDPatients hospitalized for COVID-19 exhibit diverse clinical outcomes, with outcomes for some individuals diverging over time even though their initial disease severity appears similar to that of other patients. A systematic evaluation of molecular and cellular profiles over the full disease course can link immune programs and their coordination with progression heterogeneity.METHODSWe performed deep immunophenotyping and conducted longitudinal multiomics modeling, integrating 10 assays for 1,152 Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study participants and identifying several immune cascades that were significant drivers of differential clinical outcomes.RESULTSIncreasing disease severity was driven by a temporal pattern that began with the early upregulation of immunosuppressive metabolites and then elevated levels of inflammatory cytokines, signatures of coagulation, formation of neutrophil extracellular traps, and T cell functional dysregulation. A second immune cascade, predictive of 28-day mortality among critically ill patients, was characterized by reduced total plasma Igs and B cells and dysregulated IFN responsiveness. We demonstrated that the balance disruption between IFN-stimulated genes and IFN inhibitors is a crucial biomarker of COVID-19 mortality, potentially contributing to failure of viral clearance in patients with fatal illness.CONCLUSIONOur longitudinal multiomics profiling study revealed temporal coordination across diverse omics that potentially explain the disease progression, providing insights that can inform the targeted development of therapies for patients hospitalized with COVID-19, especially those who are critically ill.TRIAL REGISTRATIONClinicalTrials.gov NCT04378777.FUNDINGNIH (5R01AI135803-03, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07, 3U19AI089992-09, 3U19AI128913-03, and 5T32DA018926-18); NIAID, NIH (3U19AI1289130, U19AI128913-04S1, and R01AI122220); and National Science Foundation (DMS2310836).

Published
2024

50. Strategies to Improve Drug Delivery Across the Blood-Brain Barrier for Glioblastoma.

Author

Narsinh, Kazim, Perez, Edgar, Haddad, Alexander, Young, Jacob, Savastano, Luis, Villanueva-Meyer, Javier, Winkler, Ethan, and de Groot, John

Subjects
Clinical trials, Convection-enhanced delivery, Drug delivery, Focused ultrasound, GBM, Glioblastoma, Laser interstitial thermal therapy, Humans, Blood-Brain Barrier, Glioblastoma, Antineoplastic Agents, Brain Neoplasms, Drug Delivery Systems, Tumor Microenvironment
Abstract

PURPOSE OF REVIEW: Glioblastoma remains resistant to most conventional treatments. Despite scientific advances in the past three decades, there has been a dearth of effective new treatments. New approaches to drug delivery and clinical trial design are needed. RECENT FINDINGS: We discuss how the blood-brain barrier and tumor microenvironment pose challenges for development of effective therapies for glioblastoma. Next, we discuss treatments in development that aim to overcome these barriers, including novel drug designs such as nanoparticles and antibody-drug conjugates, novel methods of drug delivery, including convection-enhanced and intra-arterial delivery, and novel methods to enhance drug penetration, such as blood-brain barrier disruption by focused ultrasound and laser interstitial thermal therapy. Lastly, we address future opportunities, positing combination therapy as the best strategy for effective treatment, neoadjuvant and window-of-opportunity approaches to simultaneously enhance therapeutic effectiveness with interrogation of on-treatment biologic endpoints, and adaptive platform and basket trials as imperative for future trial design. New approaches to GBM treatment should account for the blood-brain barrier and immunosuppression by improving drug delivery, combining treatments, and integrating novel clinical trial designs.

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results